MTAP

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Retrieved on: 
Wednesday, March 6, 2024

Ryvu's partner Menarini to present data on MEN1703 (SEL24), demonstrating promising anti-tumor activity in preclinical models of myelofibrosis both as a single agent and combined with ruxolitinib.

Key Points: 
  • Ryvu's partner Menarini to present data on MEN1703 (SEL24), demonstrating promising anti-tumor activity in preclinical models of myelofibrosis both as a single agent and combined with ruxolitinib.
  • "We are excited to present our latest preclinical data at the AACR Annual Meeting, showcasing our significant progress in advancing novel small molecule therapies for oncology.
  • This year, we will present data from our most advanced preclinical project on MTA-cooperative PRMT5 inhibitors, the lead program within Ryvu's synthetic lethality pipeline.
  • Ryvu has developed potentially best-in-class MTA-cooperative PRMT5 inhibitors showing favorable drug-like properties and effective PRMT5 inhibition dependent on MTA binding.

Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions

Retrieved on: 
Monday, December 18, 2023

BERKELEY HEIGHTS, N.J., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today interim results from its Phase 1, dose escalation 065-101 study of fadraciclib (“fadra”) in patients with advanced solid tumors and lymphoma.

Key Points: 
  • “The data suggest tumor sensitivity in patients with one or more of three abnormalities, CDKN2A, CDKN2B and/or MTAP deletion subject to confirmation in further studies.
  • The Phase 2 part of 065-101 is designed to evaluate fadra safety and efficacy in cohorts defined by histology and/or next generation sequencing (NGS).
  • “After retrospectively analyzing a subset of previously treated Phase 1 patients who experienced clinical benefit with fadra, we found four patients with CDKN2A, CDKN2B and/or MTAP deletions.
  • CDKN2B deletions occur in over 30% of several solid tumors, including bladder, glioma, pancreatic, esophageal, lung (incl.

Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights

Retrieved on: 
Wednesday, November 8, 2023

For TNG462, we dosed the first patient in the phase 1/2 trial in July 2023.

Key Points: 
  • For TNG462, we dosed the first patient in the phase 1/2 trial in July 2023.
  • Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, November 1-5, 2023, San Diego, CA
    In November 2023, Tango scientists presented preclinical data highlighting the potential of TNG260 in STK11-mutant cancers.
  • AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 11-15, 2023, Boston, MA
    In October 2023, Tango scientists presented five posters highlighting preclinical data from the precision oncology pipeline and synthetic lethality discovery platform.
  • The year-to-date increase is the result of out-licensing a program to Gilead for $5.0 million during the second quarter of 2023.

GT Apeiron Announces Development Candidate Nomination of Brain Penetrant PRMT5 Inhibitor, GTA182, for the Potential Treatment of MTAP-Deleted Solid Cancers

Retrieved on: 
Tuesday, October 17, 2023

SAN FRANCISCO and SHANGHAI, China, Oct. 17, 2023 (GLOBE NEWSWIRE) -- GT Apeiron Therapeutics (‘Apeiron’), a biopharmaceutical company harnessing the power of artificial intelligence to develop targeted precision therapies for unmet medical needs, today announced the development candidate nomination of GTA182, a brain penetrant protein arginine methyltransferase 5 (PRMT5) inhibitor that exhibits methylthioadenosine (MTA) cooperativity resulting in high selectivity for MTAP-deleted cancer cells while sparing MTAP-expressing non-cancer cells. This selectivity is expected to provide a more effective and safer treatment option for patients with MTAP-deleted cancers.

Key Points: 
  • This selectivity is expected to provide a more effective and safer treatment option for patients with MTAP-deleted cancers.
  • GTA182 is brain penetrant and has demonstrated tumor growth inhibition and tumor regression in in vivo pre-clinical models of glioblastoma (GBM) as well as non-CNS murine cancer models with MTAP deletions.
  • Apeiron plans to file an Investigational New Drug (IND) application in mid-2024.
  • "The nomination of our wholly–owned GTA182 program as a candidate for clinical development represents another significant milestone for Apeiron and our commitment to developing innovative therapies for cancer patients with unmet medical needs," said Mingxi Li, Ph.D., Chief Executive Officer of Apeiron.

Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics

Retrieved on: 
Sunday, October 8, 2023

The transaction was unanimously approved by both the Bristol Myers Squibb and the Mirati Boards of Directors.

Key Points: 
  • The transaction was unanimously approved by both the Bristol Myers Squibb and the Mirati Boards of Directors.
  • Mirati’s assets are a strong fit with Bristol Myers Squibb’s portfolio and innovative pipeline and represent an attractive opportunity to grow Bristol Myers Squibb’s oncology franchise.
  • Through this acquisition, Bristol Myers Squibb will add KRAZATI, an important lung cancer medicine, to its commercial portfolio.
  • Bristol Myers Squibb expects to finance the acquisition with a combination of cash and debt.

Ryvu Therapeutics to Present Preclinical Data on PRMT5 and its Synthetic Lethality Platform at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Wednesday, October 4, 2023

“During this year's AACR-NCI-EORTC conference, we will present data from our most advanced preclinical project on MTA-cooperative PRMT5 inhibitors, representing the flagship initiative within Ryvu’s synthetic lethality platform.

Key Points: 
  • “During this year's AACR-NCI-EORTC conference, we will present data from our most advanced preclinical project on MTA-cooperative PRMT5 inhibitors, representing the flagship initiative within Ryvu’s synthetic lethality platform.
  • Details on the poster presentations are as follows:
    Ryvu has developed potentially best-in-class MTA-cooperative PRMT5 inhibitors showing favorable properties and effective PRMT5 inhibition dependent on MTA.
  • Ryvu has developed a comprehensive platform using CRC model cells derived from human intestinal stem cells, patient-derived xenografts, and clinical samples.
  • Ryvu will host a webinar on Monday, October 16, at 9:30 am CEST to discuss the PRMT5 data.

Cancer Discovery Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers through Novel Approach to MTA-Cooperative PRMT5 Inhibition

Retrieved on: 
Wednesday, August 9, 2023

SAN DIEGO, Aug. 9, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, announced today Cancer Discovery published preclinical and initial clinical data from a first-in-human Phase 1/2 clinical trial of MRTX1719, a PRMT5 / methylthioadenosine (MTA)-cooperative inhibitor evaluated in methylthioadenosine phosphorylase (MTAP) deleted cancers. These results provide preclinical and early clinical proof-of-concept for this differentiated approach and demonstrate that MRTX1719 may represent a promising targeted therapy for the ~10% of cancer patients with this biomarker. The publication can be found here.

Key Points: 
  • These results provide preclinical and early clinical proof-of-concept for this differentiated approach and demonstrate that MRTX1719 may represent a promising targeted therapy for the ~10% of cancer patients with this biomarker.
  • In preclinical studies, MRTX1719 was demonstrated to be a potent, selective inhibitor of the PRMT5/MTA complex.
  • Preclinical results showed marked anti-tumor activity of MRTX1719, including regression, across lung, pancreatic, mesothelioma, and other solid tumor models.
  • "It will be important for next-generation sequencing tests to expand their panel of targets to include for markers of PRMT5 inhibition."

Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Highlights

Retrieved on: 
Monday, August 7, 2023

BOSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the second quarter ended June 30, 2023, and provided business highlights.

Key Points: 
  • “We have significantly advanced our pipeline since the first quarter, including bringing two novel agents into phase 1/2 clinical trials.
  • Alan plans to start a new company outside of our focus, which will incubate in Tango labs, facilitating his advisor role to Tango.
  • Alan played a pivotal role founding Tango and has been an integral part of the Company from inception.
  • The increase is the result of out-licensing a program to Gilead for $5.0 million during the second quarter of 2023.

Tango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients With MTAP-deleted Solid Tumors

Retrieved on: 
Monday, July 10, 2023

BOSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the phase 1/2 trial of TNG462 in patients with MTAP-deleted solid tumors.

Key Points: 
  • BOSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the phase 1/2 trial of TNG462 in patients with MTAP-deleted solid tumors.
  • TNG462 is a potentially best-in-class MTA-cooperative PRMT5 inhibitor previously granted Fast Track designation by the U.S. Food and Drug Administration.
  • The TNG462 phase 1/2 clinical trial will evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy of TNG462 in solid tumors with MTAP deletions.
  • “Dosing the first patient with our next-generation MTA-cooperative PRMT5 inhibitor, TNG462, demonstrates our deep commitment to developing transformative treatments for patients with MTAP-deleted cancers.

Ryvu Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, May 16, 2023

These molecules can selectively inhibit the growth of MTAP-deleted cancer cells in prolonged 3D culture, which correlates with the inhibition of PRMT5-dependent protein symmetric dimethylation (SDMA).

Key Points: 
  • These molecules can selectively inhibit the growth of MTAP-deleted cancer cells in prolonged 3D culture, which correlates with the inhibition of PRMT5-dependent protein symmetric dimethylation (SDMA).
  • Ryvu was also the winner in three other categories: “Investor Relations”, “Development Perspectives”, and “Products and Services Innovation”.
  • Initiation of Phase 2 trials of RVU120 in solid tumors and AML/HR-MDS is expected in 2H 2023.
  • As of May 11, 2023, Ryvu Therapeutics held $71.8M in cash, cash equivalents and bonds.